AI Summary

Merck and Moderna reported Phase 3 trial results for a personalized mRNA vaccine combined with immunotherapy in patients with melanoma. The study found the vaccine reduced the risk of disease recurrence or death by 42 percent compared with immunotherapy alone. Georgina Long, medical director of the Australian Melanoma Institute and principal investigator, described the findings as “transformative” and suggested they could shift treatment approaches for earlier‑stage melanoma. The trial’s outcomes highlight the potential of mRNA‑based therapies in aggressive skin cancer.

AI summaries can be wrong sometimes—always verify important details using the source article.